Abstract:ABSTRACTIntroduction Precision medicine based on the driver genes mutation status is the current systemic therapeutic paradigm in patients with lung cancer. Next-generation sequencing (NGS) has emerged as a powerful platform for molecular diagnosis by virtue of high-throughput and massively parallel sequencing. Liquid biopsy also enabled the dynamic monitoring and comprehensive profiling of lung cancer in a noninvasive manner. However, challenges remain in the field of technology and clinical applications, especially in the era of immunotherapy.Areas covered Here, we update the role of NGS in the context of lung cancer screening, molecular diagnosis, predictive and prognostic biomarkers, and guiding personalized treatment.Expert opinion The NGS application for actable genomic alternation has greatly changed the therapeutic landscape in patients with lung cancer including perioperative setting and advanced stage. Meanwhile, emerging evidence has shown the potential of other applications such as early screening and detection, and MRD. However, challenges remain such as the lack of standardized protocols across different platforms and bioinformatics analysis pipelines, and the complexity of interpreting and leveraging numerous genomic mutation messages for therapy selection. Future research is needed to overcome these challenges and expand the applications of NGS to other aspects such as immunotherapy.KEYWORDS: Next-generation sequencing (NGS)precision medicinelung cancermolecular diagnosticsliquid biopsy Article highlights NGS is a powerful tool for identifying genomic alterations in lung cancer, providing a deep understanding of tumor biology and aiding clinical decision making.Liquid biopsy, a minimally invasive alternative to tissue biopsy, allows for the detection of tumor-derived genetic material in blood or other body fluids, enabling real-time monitoring of tumor progression or response to therapy.The use of NGS in liquid biopsy has revolutionized the field of lung cancer diagnosis and management, facilitating the identification of actionable mutations and the development of personalized treatment strategies.Challenges still exist in the implementation of NGS-based biopsy in clinical practice, including the need for standardized protocols, optimization of sequencing platforms, and interpretation of complex data, the clinical application of MRD detection, early diagnosis, and biomarkers for immunotherapy.Declaration of interestsThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Additional informationFundingThis work was sponsored by grants from the National Natural Science Foundation of China (No. 82172869 and No. 81972167) and the Program of Shanghai Academic Research Leader (No. 21XD1423200).

Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine

Clinical significance of multi-sample next-generation sequencing for detection of gene mutations in non-small cell lung cancer

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls

Next-generation sequencing as a valuable tool for mutational spectrum in advanced-stage NSCLC patients

Recent Advance of Next-Generation Sequencing in Patients with Lung Cancer

The Utilization of Next-Generation Sequencing to Detect Somatic Mutations and Predict Clinical Prognosis of Chinese Non-Small Cell Lung Cancer Patients

Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression

Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): What Happens after Panel Testing by Next Generation Sequencing (NGS)?

Assessment of the Clinical Application of Detecting EGFR, KRAS, PIK3CA and BRAF Mutations in Patients with Non-Small Cell Lung Cancer Using Next-Generation Sequencing

Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study

Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice

CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer

Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice

Advancements in NSCLC

Identification of gene variation feature for targeted therapy of non-small cell lung cancer through combined method of DNA and RNA sequencing

Validating a Targeted Next-Generation Sequencing Assay and Profiling Somatic Variants in Chinese Non-Small Cell Lung Cancer Patients

Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments

High Sensitive and Non-invasive Ctdnas Sequencing Facilitate Clinical Diagnosis and Clinical Guidance of Non-small Cell Lung Cancer Patient: A Time Course Study